| |
NewswireTODAY - /newswire/ -
Nottingham, United Kingdom, 2010/07/06 - Novozymes Biopharma, part of Novozymes, world leader in bioinnovation, is offering customers free evaluation samples of the company's award-winning Bacillus-based sodium hyaluronate.
|
| |
The sample program precedes the 2011 launch of Novozymes Biopharma's new cGMP facility in Tianjin, China and will provide a unique opportunity to experience first-hand the quality of the product that will be manufactured at the cGMP Q7 validated site.
Novozymes Biopharma's sodium hyaluronate is 100% free of animal-derived raw materials and organic solvent remnants. The product is fermented using a unique non-pathogenic and well documented production strain, Bacillus subtilis, offering the medical device and pharmaceutical industries a range of benefits including increased safety, purity, batch-to-batch consistency and stability in large scale. The company's sodium hyaluronate can be used in a wide range of applications in the pharmaceutical sector for improved drug delivery as well as in medical device application areas such as ophthalmology, dermatology, osteoarthritis, dermal fillers, adhesion prevention, coating and wound healing.
"We are delighted to offer new and existing users the opportunity to pilot Novozymes Biopharma's innovative sodium hyaluronate", comments Hans Ole Klingenberg, Product Director at Novozymes Biopharma. We are developing our new cGMP facility in China to expand the use of sodium hyaluronate and to set a new bench-mark for quality and consistency. This sample program precedes the opening of our new facility and is a unique opportunity for customers to sample our product and experience its benefits in drug delivery and medical device applications."
Samples are available for a limited time.
Novozymes Biopharma's sodium hyaluronate was awarded the CPhI Gold Innovation Award for its innovative production process allowing for better safety and improved consistency.
About Novozymes
Novozymes (novozymes.com) is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources.
With over 700 products used in 130 countries, Novozymes' bioinnovations improve industrial performance and safeguard the world's resources by offering superior and sustainable solutions for tomorrow's ever-changing marketplace.
Novozymes' natural solutions enhance and promote everything from removing trans fats in cooking, to advancing biofuels to power the world tomorrow. Our never-ending exploration of nature's potential is evidenced by over 6,000 patents, showing what is possible when nature and technology join forces.
Our 5,000+ employees working in research, production and sales around the world are committed to shaping business today and our world tomorrow.
Contact: Novozymes Biopharma: Sally Vernon, Customer Communications Manager.
Press and media:
Johan Melchior, T: +45 4446 0690, M: +45 3077 0690
René Tronborg, T: +45 4446 2274, M: +45 3077 2274
Paige Donnelly (USA), T: +1 919 494 3209, M: +1 919 218 4501
Investor relations:
Tobias Bjørklund, T:+45 4446 8682, M: +45 3077 8682
Thomas Bomhoff (USA), T: +1 919 494 3483, M: +1 919 649 2565
|
SYKE[.]novozymes.com 
